Total Payments
$8,060
2024 Payments
$2,329
Companies
63
Transactions
494
Medicare Patients
5,838
Medicare Billing
$573,551
Payment Breakdown by Category
Food & Beverage$7,167 (88.9%)
Education$892.78 (11.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,167 | 459 | 88.9% |
| Education | $892.78 | 35 | 11.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $835.48 | 60 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $626.48 | 56 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $605.22 | 24 | $0 (2024) |
| Merck Sharp & Dohme LLC | $541.40 | 35 | $0 (2024) |
| Genentech USA, Inc. | $475.01 | 38 | $0 (2024) |
| PFIZER INC. | $434.18 | 30 | $0 (2024) |
| Exelixis Inc. | $350.83 | 30 | $0 (2019) |
| Janssen Biotech, Inc. | $319.45 | 17 | $0 (2024) |
| Incyte Corporation | $244.02 | 9 | $0 (2024) |
| Amgen Inc. | $243.68 | 17 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,329 | 97 | AstraZeneca Pharmaceuticals LP ($457.92) |
| 2023 | $542.85 | 27 | PFIZER INC. ($85.99) |
| 2022 | $174.09 | 10 | Rigel Pharmaceuticals, Inc. ($30.42) |
| 2021 | $35.87 | 3 | Blueprint Medicines Corporation ($12.45) |
| 2020 | $447.60 | 26 | Novartis Pharmaceuticals Corporation ($67.85) |
| 2019 | $1,277 | 90 | E.R. Squibb & Sons, L.L.C. ($176.85) |
| 2018 | $1,477 | 115 | Merck Sharp & Dohme Corporation ($177.03) |
| 2017 | $1,777 | 126 | Novartis Pharmaceuticals Corporation ($265.85) |
All Payment Transactions
494 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $19.75 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Novocure Inc. | Optune (Device) | Food and Beverage | Cash or cash equivalent | $133.31 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: Oncology | ||||||
| 10/01/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: Oncology | ||||||
| 09/18/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $26.44 | General |
| Category: Oncology | ||||||
| 09/12/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: Oncology | ||||||
| 09/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: Oncology | ||||||
| 09/09/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: Oncology | ||||||
| 09/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $34.67 | General |
| Category: ONCOLOGY | ||||||
| 09/04/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: Oncology | ||||||
| 09/03/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: Oncology | ||||||
| 09/03/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $12.99 | General |
| Category: Oncology | ||||||
| 08/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $31.82 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $33.98 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: Immunology | ||||||
| 08/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $15.72 | General |
| Category: Oncology | ||||||
| 08/19/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $14.80 | General |
| 08/13/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $30.76 | General |
| Category: Oncology | ||||||
| 08/12/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $28.89 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $23.12 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,297 | 1,840 | $323,958 | $120,400 |
| 2022 | 9 | 1,316 | 2,035 | $356,536 | $139,623 |
| 2021 | 11 | 1,497 | 2,099 | $317,999 | $142,044 |
| 2020 | 11 | 1,728 | 2,906 | $560,813 | $171,483 |
Total Patients
5,838
Total Services
8,880
Medicare Billing
$573,551
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 451 | 852 | $165,118 | $61,832 | 37.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 474 | 558 | $73,823 | $26,295 | 35.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 59 | 77 | $22,181 | $8,531 | 38.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 54 | 54 | $19,644 | $7,550 | 38.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 56 | 56 | $15,023 | $5,662 | 37.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 27 | 27 | $7,346 | $2,770 | 37.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 22 | 25 | $6,400 | $2,549 | 39.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 14 | 16 | $4,272 | $1,618 | 37.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 57 | 58 | $4,181 | $1,350 | 32.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 14 | 14 | $2,323 | $783.36 | 33.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 28 | 31 | $1,971 | $757.64 | 38.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 11 | 35 | $1,085 | $422.01 | 38.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 30 | 37 | $592.00 | $281.57 | 47.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 485 | 1,069 | $201,890 | $81,448 | 40.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 586 | 714 | $90,232 | $33,291 | 36.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 101 | 102 | $27,138 | $10,581 | 39.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 55 | 61 | $17,369 | $6,810 | 39.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 22 | 22 | $7,887 | $3,068 | 38.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 29 | 29 | $4,817 | $1,718 | 35.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 14 | $3,809 | $1,388 | 36.4% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 13 | 13 | $2,622 | $1,029 | 39.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 11 | 11 | $771.52 | $289.89 | 37.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 521 | 899 | $140,550 | $63,310 | 45.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 563 | 740 | $75,051 | $35,552 | 47.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 182 | 217 | $47,840 | $22,796 | 47.7% |
About Dr. Devaki Siva, MD
Dr. Devaki Siva, MD is a Hematology & Oncology healthcare provider based in Lakewood Ranch, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2007. The National Provider Identifier (NPI) number assigned to this provider is 1982823290.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Devaki Siva, MD has received a total of $8,060 in payments from pharmaceutical and medical device companies, with $2,329 received in 2024. These payments were reported across 494 transactions from 63 companies. The most common payment nature is "Food and Beverage" ($7,167).
As a Medicare-enrolled provider, Siva has provided services to 5,838 Medicare beneficiaries, totaling 8,880 services with total Medicare billing of $573,551. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Lakewood Ranch, FL
- Active Since 04/25/2007
- Last Updated 01/30/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1982823290
Products in Payments
- OPDIVO (Biological) $534.45
- KEYTRUDA (Biological) $502.17
- Cabometyx (Drug) $350.83
- LYNPARZA (Drug) $315.39
- XTANDI (Drug) $224.45
- KISQALI (Drug) $195.86
- IMBRUVICA (Drug) $195.79
- TASIGNA (Drug) $176.39
- Enhertu (Drug) $146.36
- Optune (Device) $133.31
- JAKAFI (Drug) $124.71
- VERZENIO (Drug) $120.43
- VELCADE (Drug) $110.50
- TIBSOVO (Drug) $108.34
- Kyprolis (Biological) $106.07
- BESREMI (Drug) $97.41
- AFINITOR (Drug) $90.93
- ENHERTU (Biological) $88.55
- Xtandi (Drug) $88.24
- Perjeta (Biological) $87.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.